CA2787331A1 - Aromatic-cationic peptides and uses of same - Google Patents

Aromatic-cationic peptides and uses of same Download PDF

Info

Publication number
CA2787331A1
CA2787331A1 CA2787331A CA2787331A CA2787331A1 CA 2787331 A1 CA2787331 A1 CA 2787331A1 CA 2787331 A CA2787331 A CA 2787331A CA 2787331 A CA2787331 A CA 2787331A CA 2787331 A1 CA2787331 A1 CA 2787331A1
Authority
CA
Canada
Prior art keywords
lys
dmt
arg
phe
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2787331A
Other languages
English (en)
French (fr)
Inventor
Hazel H. Szeto
Peter W. Schiller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut de Recherches Cliniques de Montreal IRCM
Cornell University
Original Assignee
Institut de Recherches Cliniques de Montreal IRCM
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut de Recherches Cliniques de Montreal IRCM, Cornell University filed Critical Institut de Recherches Cliniques de Montreal IRCM
Priority to CA3008993A priority Critical patent/CA3008993A1/en
Publication of CA2787331A1 publication Critical patent/CA2787331A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA2787331A 2010-01-25 2011-01-24 Aromatic-cationic peptides and uses of same Abandoned CA2787331A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3008993A CA3008993A1 (en) 2010-01-25 2011-01-24 Aromatic-cationic peptides and uses of same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29806210P 2010-01-25 2010-01-25
US61/298,062 2010-01-25
PCT/US2011/022247 WO2011091357A1 (en) 2010-01-25 2011-01-24 Aromatic-cationic peptides and uses of same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3008993A Division CA3008993A1 (en) 2010-01-25 2011-01-24 Aromatic-cationic peptides and uses of same

Publications (1)

Publication Number Publication Date
CA2787331A1 true CA2787331A1 (en) 2011-07-28

Family

ID=44307257

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2787331A Abandoned CA2787331A1 (en) 2010-01-25 2011-01-24 Aromatic-cationic peptides and uses of same
CA3008993A Abandoned CA3008993A1 (en) 2010-01-25 2011-01-24 Aromatic-cationic peptides and uses of same

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3008993A Abandoned CA3008993A1 (en) 2010-01-25 2011-01-24 Aromatic-cationic peptides and uses of same

Country Status (8)

Country Link
US (6) US20120329730A1 (https=)
EP (4) EP2733150A1 (https=)
JP (2) JP2013518057A (https=)
CN (2) CN104725472A (https=)
AU (2) AU2011207432A1 (https=)
CA (2) CA2787331A1 (https=)
HK (1) HK1208686A1 (https=)
WO (1) WO2011091357A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2964555T3 (es) * 2009-08-24 2024-04-08 Stealth Biotherapeutics Inc Péptido para uso en la prevención o tratamiento de la degeneración macular
JP2013521231A (ja) * 2010-02-26 2013-06-10 ユニバーシティ オブ フロリダ リサーチ ファウンデーション インコーポレイテッド ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する
EP3375449A1 (en) 2010-03-15 2018-09-19 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
EP3290433A1 (en) * 2010-05-03 2018-03-07 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
CN102327600A (zh) * 2011-09-14 2012-01-25 中国人民解放军军事医学科学院放射与辐射医学研究所 用于预防和治疗辐射损伤的rx31肽
CN106913860A (zh) 2011-09-29 2017-07-04 梅约医学教育与研究基金会 芳族阳离子肽和使用它们的方法
EP2788013A4 (en) * 2011-12-09 2015-08-19 Stealth Peptides Int Inc AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
CN104271146A (zh) * 2012-03-30 2015-01-07 康肽德生物医药技术有限公司 用于预防和治疗神经病的方法和组合物
CN105753939A (zh) * 2012-04-12 2016-07-13 康德生物医疗技术公司 芳香族阳离子肽及其用途
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
US20140294902A1 (en) * 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide antagonists
WO2014210056A1 (en) * 2013-06-27 2014-12-31 Stealth Peptides International, Inc. Peptide therapeutics and methods for using same
CA2920735A1 (en) * 2013-08-12 2015-02-19 Stealth Biotherapeutics Corp Combination therapy for the treatment of ischemia-reperfusion injury
JP2016540762A (ja) * 2013-12-02 2016-12-28 ステルス バイオセラピューティックス コープ 白斑の治療のための組成物及び方法
HRP20211448T1 (hr) 2014-05-16 2021-12-24 Protagonist Therapeutics, Inc. Alfa4beta7 integrin tioeter peptidni antagonisti
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
WO2016054411A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
EP3265109B1 (en) 2015-03-06 2020-10-21 Stealth BioTherapeutics Corp Processes for preparing pharmaceutically relevant peptides
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP6533723B2 (ja) * 2015-09-11 2019-06-19 キユーピー株式会社 抗酸化剤
CA3006698A1 (en) * 2015-11-30 2017-06-08 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CN109069572A (zh) 2015-12-31 2018-12-21 康德生物医疗技术公司 包含肽的治疗性组合物和其用途
CA3017359A1 (en) 2016-03-11 2017-09-14 Scott M. Duncan Crystalline salt forms
WO2017180535A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
EP3681900A4 (en) * 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND THEIR USES
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
WO2020014646A1 (en) 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US12252554B2 (en) 2018-12-18 2025-03-18 Stealth Biotherapeutics Inc. Analogs that target mitochondrial diseases
JP7534382B2 (ja) 2019-07-10 2024-08-14 プロタゴニスト セラピューティクス， インコーポレイテッド インターロイキン－２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
AU2021209086A1 (en) 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3167751A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP7397239B2 (ja) 2020-11-20 2023-12-12 ヤンセン ファーマシューティカ エヌ．ベー． インターロイキン－２３受容体のペプチド阻害剤の組成物
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法
EP4370146A4 (en) 2021-07-14 2025-05-21 Janssen Biotech, Inc. Lipidated peptide inhibitors of the interleukin-23 receptor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0273696A2 (en) * 1987-01-02 1988-07-06 Merck & Co. Inc. Renin inhibitors containing histidine replacements
IE903958A1 (en) * 1989-11-06 1991-05-08 Erba Carlo Spa Reduced irreversible bombesin antagonists
JPH06509075A (ja) * 1991-07-01 1994-10-13 ユニヴァーシティ　テクノロジーズ　インターナショナル　インコーポレイテッド ＧｎＲＨ及び他の生物学的に活性なリガンドの非感度低下性類縁体
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
EP1599216B9 (en) * 2003-02-04 2015-02-11 Cornell Research Foundation, Inc. Methods for preventing mitochondrial permeability transition
CA3024434A1 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
EP2712620A1 (en) * 2008-02-07 2014-04-02 Cornell University Methods for Preventing or Treating Insulin Resistance
EP3741381B1 (en) * 2008-02-26 2024-04-24 Cornell University A peptide for use for prevention and treatment of acute renal injury

Also Published As

Publication number Publication date
HK1208686A1 (en) 2016-03-11
EP2528934A1 (en) 2012-12-05
JP2013518057A (ja) 2013-05-20
CN104725472A (zh) 2015-06-24
WO2011091357A1 (en) 2011-07-28
US20170008925A1 (en) 2017-01-12
AU2011207432A1 (en) 2012-08-02
US20130316964A1 (en) 2013-11-28
EP3018138A1 (en) 2016-05-11
US20180244721A1 (en) 2018-08-30
EP2848628A1 (en) 2015-03-18
JP2016000750A (ja) 2016-01-07
US20120329730A1 (en) 2012-12-27
US20150005242A1 (en) 2015-01-01
EP2528934A4 (en) 2013-08-21
EP2733150A1 (en) 2014-05-21
AU2016200747A1 (en) 2016-02-25
US20190330272A1 (en) 2019-10-31
CA3008993A1 (en) 2011-07-28
CN102834408A (zh) 2012-12-19

Similar Documents

Publication Publication Date Title
US20190330272A1 (en) Aromatic-cationic peptides and uses of same
US11083772B2 (en) Methods and compositions for the prevention or treatment of Barth Syndrome
EP3009141A1 (en) Aromatic-cationic peptides and uses of same
CN116440247A (zh) 治疗线粒体疾病的方法
EP3049096B1 (en) Use of aromatic-cationic peptides to treat niemann-pick disease characterised by cholesterol-induced mitochondrial dysfunction
AU2017261638A1 (en) Aromatic-cationic peptides and uses of same
US20200308220A1 (en) Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
HK1179977A (en) Aromatic-cationic peptides and uses of same

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160108

FZDE Discontinued

Effective date: 20190625